Walleye Capital LLC Purchases New Shares in Agenus Inc. $AGEN

Walleye Capital LLC purchased a new position in Agenus Inc. (NASDAQ:AGEN) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 198,288 shares of the biotechnology company’s stock, valued at approximately $906,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Siren L.L.C. acquired a new stake in shares of Agenus in the first quarter valued at about $752,000. AQR Capital Management LLC lifted its stake in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares in the last quarter. Strs Ohio purchased a new position in Agenus in the 1st quarter valued at about $214,000. JPMorgan Chase & Co. boosted its holdings in Agenus by 608.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock worth $359,000 after buying an additional 67,530 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Agenus during the 2nd quarter worth approximately $272,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Price Performance

Shares of Agenus stock opened at $4.09 on Thursday. The stock’s 50 day simple moving average is $4.13 and its 200-day simple moving average is $4.63. The stock has a market cap of $139.10 million, a P/E ratio of -1.92 and a beta of 1.51. Agenus Inc. has a 1-year low of $1.38 and a 1-year high of $7.34.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 EPS for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The company had revenue of $30.24 million during the quarter, compared to analysts’ expectations of $80.39 million. As a group, research analysts expect that Agenus Inc. will post -12.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AGEN has been the topic of several research reports. HC Wainwright restated a “buy” rating on shares of Agenus in a research report on Monday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a research note on Monday. Finally, Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Agenus has an average rating of “Hold” and a consensus price target of $14.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.